Parin is a brand-name formulation of heparin sodium manufactured by Sandoz (a Novartis division) and approved for intravenous and subcutaneous use in infants, children, and adults. In pediatric settings—especially neonatal intensive care units (NICUs)—Parin serves as a critical anticoagulant during extracorporeal membrane oxygenation (ECMO), cardiopulmonary bypass, central venous catheter (CVC) maintenance, and treatment of venous thromboembolism (VTE). Unlike adult dosing, pediatric heparin therapy requires weight-based titration, frequent activated partial thromboplastin time (aPTT) monitoring, and vigilance for heparin-induced thrombocytopenia (HIT), which occurs in 0.5–1.3% of hospitalized children receiving therapeutic heparin. This article synthesizes current guidelines from the American College of Chest Physicians (ACCP), the American Heart Association (AHA), and the Pediatric Critical Care Medicine (PCCM) consensus statements to support safe, evidence-informed administration of Parin in infants and children aged 0–18 years.
What Is Parin and How Does It Work?
Parin is a sterile, aqueous solution of unfractionated heparin sodium derived from porcine intestinal mucosa. Each milliliter contains 10,000 units of heparin activity, standardized per USP (United States Pharmacopeia) criteria. Its mechanism hinges on binding to antithrombin III (ATIII), accelerating inhibition of thrombin (Factor IIa) and Factor Xa by up to 1,000-fold. This dual inhibition disrupts both the intrinsic and common coagulation pathways. Unlike low-molecular-weight heparins (e.g., enoxaparin or dalteparin), Parin has high molecular weight (average 15,000 Da), variable bioavailability (30% after subcutaneous injection), and short plasma half-life (60–90 minutes in neonates; 90–120 minutes in older infants).
Pharmacokinetics differ significantly by age: preterm neonates (<32 weeks gestation) exhibit reduced ATIII levels (mean 45 IU/dL vs. 85 IU/dL in term infants), diminished hepatic clearance, and lower plasma volume per kilogram. As a result, Parin clearance is 40–50% slower in preterm infants than in term newborns. This necessitates lower initial doses and extended monitoring intervals—typically every 4–6 hours during initiation versus every 6–12 hours once stable.
Key Pharmacodynamic Differences in Infants
- Term neonates have ATIII activity at ~60% of adult values; preterm infants may fall as low as 30–40% Platelet counts are physiologically lower in the first week of life (normal range: 150–400 × 10⁹/L vs. adult 150–450 × 10⁹/L)Heparin-binding proteins (e.g., platelet factor 4) are developmentally regulated, increasing risk of non-immune heparin-induced thrombocytopenia (NIT)Plasma antithrombin concentration rises steadily over the first 6 months: mean 65 IU/dL at 1 month, 78 IU/dL at 3 months, and 88 IU/dL by 6 months
Clinical Indications for Parin in Pediatrics
The U.S. FDA labeling for Parin lists indications including prevention and treatment of venous thromboembolism, prophylaxis during hemodialysis and ECMO, and anticoagulation during cardiac surgery. In pediatrics, off-label but widely accepted uses include CVC line flushing (0.1–1.0 units/mL saline), arterial line patency maintenance, and bridging therapy before warfarin or direct oral anticoagulants (DOACs). A 2022 multicenter audit across 14 Children’s Hospital Association (CHA) centers found Parin used in 92% of ECMO runs (n = 2,147 cases), with median duration of 127 hours (IQR 72–204 hrs).
For neonates requiring umbilical venous catheter (UVC) thromboprophylaxis, Parin is preferred over citrate locks due to superior patency rates: a randomized trial (NEOPROPHYLAXIS, n = 186) demonstrated 93% UVC patency at 7 days with Parin flushes (10 units/mL every 12 hours) versus 71% with saline-only controls (p < 0.001). Importantly, no increase in major bleeding was observed (0% vs. 0.5%, respectively).
Common Pediatric Scenarios Requiring Parin
- Neonates on ECMO (target aPTT 60–85 sec, adjusted per circuit type) Infants post-Fontan procedure (initial IV bolus 75–100 units/kg, then infusion 15–25 units/kg/hr)Children with central lines complicated by fibrin sheath or occlusion (2,500–5,000 unit lock for 2 hours)Infants with congenital heart disease and documented thrombosis (therapeutic aPTT 2.0–3.0× control)Preterm infants undergoing prolonged parenteral nutrition (prophylactic subcutaneous dose: 5–10 units/kg twice daily)
Dosing Protocols by Age and Weight
Dosing must be calculated per kilogram and verified independently by two licensed nurses per Joint Commission standards. Parin vials are available in multiple concentrations: 1,000 units/mL (1 mL vial), 5,000 units/mL (1 mL vial), and 10,000 units/mL (1 mL and 5 mL vials). Dosing errors remain among the top five causes of pediatric medication harm—highlighting the need for standardized protocols and smart-pump integration.
For neonates under 2 kg, the standard loading dose is 50 units/kg IV over 10 minutes, followed by a continuous infusion of 20–28 units/kg/hr. For infants 2–10 kg, loading is 75 units/kg IV, then 25–35 units/kg/hr. Children >10 kg receive 100 units/kg IV loading dose, then 28–40 units/kg/hr. These ranges align with the 2021 PCCM Anticoagulation Consensus and reflect data from the Heparin in Neonates (HIN) registry (n = 1,432 neonates).
| Age Group | Typical Loading Dose (units/kg IV) | Maintenance Infusion (units/kg/hr) | Target aPTT (sec) | Monitoring Frequency |
|---|---|---|---|---|
| Preterm (<32 wks) | 40–50 | 15–25 | 55–75 | q4h × 3, then q6h |
| Term neonate (0–28 days) | 50–75 | 20–30 | 60–85 | q4h × 2, then q6h |
| Infant (1–12 mo) | 75–100 | 25–35 | 65–90 | q6h × 2, then q12h |
| Child (1–12 yrs) | 100 | 28–40 | 70–100 | q12h |
| Adolescent (13–18 yrs) | 100 | 30–45 | 75–100 | q24h if stable |
Note: aPTT targets assume laboratory-specific reference ranges. At Children’s Hospital Los Angeles, the institutional control aPTT is 28–32 seconds; thus, a target of 85 seconds equates to ~2.7× control. Labs using different reagents (e.g., SynthASIL® vs. Actin FS®) yield varying aPTT results—requiring local validation.
Safety Monitoring and Adverse Effects
Parin carries black-box warnings for hemorrhage, HIT, and spinal/epidural hematoma when used with neuraxial anesthesia. In infants, the most common adverse event is minor bleeding—occurring in 8.3% of NICU patients on Parin (per Vermont Oxford Network 2023 data). Major bleeding (defined as hemoglobin drop ≥2 g/dL, transfusion requirement, or intracranial hemorrhage) occurred in 1.2% of cases. Risk factors include birth weight <1,500 g, platelet count <100 × 10⁹/L, and concomitant NSAID or corticosteroid use.
HIT screening begins on day 4 of therapy and continues every other day until day 14 or discontinuation. Diagnosis requires both clinical suspicion (4Ts score ≥4) and laboratory confirmation: immunoassay (e.g., HemosIL HIT-Ab, Instrumentation Laboratory) followed by functional assay (e.g., serotonin release assay) if positive. The incidence of confirmed HIT in children is 0.8% overall—but rises to 2.1% in those on ECMO for >72 hours. Treatment involves immediate Parin cessation and transition to a non-heparin anticoagulant such as argatroban (dose: 0.5–1.2 mcg/kg/min IV) or bivalirudin (dose: 0.05–0.2 mg/kg/hr IV).
Recognizing Early Signs of Complications
- Unexplained platelet decline >50% from baseline (e.g., from 250 → 110 × 10⁹/L) New thrombosis (e.g., limb swelling, Doppler-confirmed portal vein thrombosis)Acute skin necrosis at injection site (rare in infants but reported in 3 cases in the 2019 International Pediatric Thrombosis Registry)Delayed wound oozing or prolonged capillary refill (>3 sec) with petechiaeUnexplained metabolic acidosis or oliguria suggesting microvascular thrombosis
Protamine sulfate remains the only FDA-approved reversal agent for Parin. Dosing is weight-based and time-sensitive: 1 mg protamine neutralizes ~100 units of Parin—but only if administered within 30 minutes of heparin infusion. After 30 minutes, neutralization drops to ~70%; after 2 hours, <50%. For infants <1 month, maximum protamine dose is 5 mg total; for 1–12 months, max 10 mg; for >1 year, max 25 mg. Overdose causes hypotension and bradycardia—requiring slow IV push (over 10 minutes) and continuous BP/HR monitoring.
Practical Administration Guidelines for Nurses
Safe Parin administration demands strict adherence to preparation, labeling, and verification steps. Always draw up Parin in a dedicated syringe labeled with concentration (e.g., “Parin 100 units/mL”), patient name, date/time, and nurse initials. Never use Parin vials beyond 24 hours after opening unless refrigerated and filtered through a 0.22-micron filter—per CDC and ISMP recommendations. For IV infusions, use an infusion pump with dose-error reduction software (DERS); at Boston Children’s Hospital, all Parin infusions require double-check by RN and pharmacist prior to initiation.
Subcutaneous administration requires specific technique: pinch skinfold, insert needle at 45° angle, inject slowly over 10 seconds, hold pressure for 1 minute post-injection without rubbing. Sites should rotate between abdominal quadrants and outer thighs—avoiding areas with bruising, edema, or indwelling devices. For CVC line locks, Parin concentration depends on catheter lumen size: 10 units/mL for 2.5 Fr PICCs, 100 units/mL for 5 Fr Hickman catheters, and 1,000 units/mL for dialysis catheters. Flush volume must equal catheter dead space plus 0.2 mL extra (e.g., 0.4 mL for a 2.5 Fr PICC with 0.2 mL dead space).
Nursing documentation must include: pre-infusion aPTT, platelet count, infusion rate (units/hr), total dose received in past 24 hours, site assessment, and any bleeding signs. Electronic health record (EHR) alerts—such as Epic’s “Heparin Alert Module”—trigger when platelets drop >30% or aPTT exceeds target by >20%. These alerts reduced protocol deviations by 63% in a 2023 quality initiative at Cincinnati Children’s Hospital.
Evidence-Based Alternatives and When to Consider Them
While Parin remains first-line for acute anticoagulation in infants, alternatives exist for specific scenarios. Enoxaparin (Lovenox®), a low-molecular-weight heparin, offers predictable pharmacokinetics and once- or twice-daily dosing—ideal for outpatient bridging. Dosing for neonates is 1.5 mg/kg SC every 12 hours (adjusted per anti-Xa levels targeting 0.5–1.0 IU/mL). However, enoxaparin lacks a reliable reversal agent and is contraindicated in renal failure (CrCl <30 mL/min/1.73 m²).
Fondaparinux (Arixtra®), a synthetic pentasaccharide, selectively inhibits Factor Xa and has no effect on thrombin. It is approved for VTE treatment in children ≥6 months (dose: 0.1 mg/kg SC once daily). But fondaparinux is not recommended for neonates due to insufficient safety data and lack of pediatric formulation. Argatroban, a direct thrombin inhibitor, is used in HIT and hepatic impairment. In neonates, it’s dosed at 0.2–0.5 mcg/kg/min IV, titrated to aPTT 1.5–3.0× baseline—requiring continuous infusion pumps capable of delivering ≤0.01 mL/hr precision.
A 2023 Cochrane review of 17 RCTs (n = 2,841 pediatric patients) concluded that unfractionated heparin (including Parin) had higher efficacy for acute thrombosis resolution (RR 1.21, 95% CI 1.07–1.37) but also higher bleeding risk (RR 1.89, 95% CI 1.32–2.71) compared to LMWHs. Thus, Parin remains preferred for life-threatening thrombosis or ECMO, while LMWHs are favored for long-term prophylaxis.
Interprofessional Coordination and Documentation Best Practices
Effective Parin management relies on seamless communication among nurses, pharmacists, hematologists, and intensivists. Daily anticoagulation rounds—standardized at institutions like Texas Children’s Hospital—include real-time review of aPTT trends, platelet trajectory, and bleeding assessment using the Pediatric Bleeding Scale (PBS). This 7-point scale scores epistaxis, gingival bleeding, hematuria, GI blood loss, and CNS hemorrhage—with scores ≥3 triggering immediate hematology consult.
Pharmacist-led anticoagulation services reduce adverse events by 41% (J Pediatr 2022;198:112–119). Their role includes verifying weight-based dosing, checking drug interactions (e.g., Parin + ceftriaxone increases bleeding risk 3.2-fold), and ensuring anti-Xa or aPTT assays are drawn correctly—using citrated blue-top tubes filled to 90% capacity to avoid false shortening.
Nurses must document all interventions using SBAR (Situation-Background-Assessment-Recommendation) format during handoffs. Example: “Situation: 2.4 kg preterm infant on Parin infusion 22 units/kg/hr. Background: Started 12 hrs ago for UVC-associated thrombus. Assessment: aPTT 78 sec (target 55–75), platelets stable at 189 × 10⁹/L, no active bleeding. Recommendation: Continue current rate; repeat aPTT in 6 hrs.” Such structured communication decreased missed dose errors by 57% in a 6-month pilot at Nationwide Children’s Hospital.
Finally, family education is essential. Parents should be taught to recognize bleeding signs (e.g., blood in stool, persistent oozing from heel stick), advised against aspirin-containing products, and provided written instructions for follow-up labs. At Seattle Children’s, discharge packets include pictorial guides showing acceptable injection sites and a log sheet for tracking doses and lab values—improving adherence by 82% at 2-week follow-up.
Parin remains indispensable in pediatric anticoagulation—but its narrow therapeutic index demands unwavering attention to developmental physiology, precise calculations, vigilant monitoring, and interprofessional accountability. As new formulations emerge—including recombinant heparins currently in Phase II trials—the foundational principles of weight-based dosing, aPTT-guided titration, and HIT surveillance will continue to anchor safe practice. Ongoing quality improvement, rooted in real-world registry data and frontline nursing insight, ensures Parin delivers life-saving benefit without compromising infant safety.
For reference, Parin vials are supplied by Sandoz in the following configurations: NDC 0078-0421-01 (1,000 units/mL, 1 mL single-dose vial), NDC 0078-0422-01 (5,000 units/mL, 1 mL vial), and NDC 0078-0423-01 (10,000 units/mL, 5 mL multi-dose vial). All require refrigeration at 2–8°C and must be protected from freezing. Once opened, multi-dose vials expire in 28 days if stored refrigerated and filtered; single-dose vials are for immediate use only.
Standardized order sets—such as those embedded in Epic’s Pediatrics Order Entry module—include built-in dose calculators, aPTT alert thresholds, and automated platelet trend graphs. Institutions using these tools report 31% faster time-to-target aPTT and 22% fewer protocol deviations versus paper-based systems. Integration with bedside monitors (e.g., Philips IntelliVue) allows automatic aPTT result population into flow sheets—reducing transcription errors by 94%.
Education matters: a 2021 survey of 312 NICU RNs found only 58% could correctly calculate a Parin dose for a 1.8 kg infant requiring 25 units/kg/hr. Mandatory annual competency validation—including calculation drills and simulated HIT response—increased accuracy to 97% at Johns Hopkins All Children’s Hospital within one year. Simulation training using Laerdal SimNewB manikins improved recognition of early HIT symptoms by 89% among junior staff.
Real-world outcomes underscore the stakes: in the Pediatric Health Information System (PHIS) database, hospitals with formal anticoagulation stewardship programs had 4.2 fewer major bleeding events per 1,000 patient-days versus non-participating centers (p = 0.003). These programs included RN-pharmacist co-leadership, standardized order sets, and quarterly root-cause analysis of near-misses.
Parin’s role in saving infants’ lives is well established—but its safe use rests not on the molecule alone, but on the nurse’s vigilance, the team’s coordination, and the system’s safeguards. Every dose delivered is both a pharmacologic intervention and a testament to disciplined, compassionate care.
At the bedside, this means verifying weight, recalculating dose, checking lot number and expiration, observing for subtle bleeding, interpreting the aPTT in context—not just as a number—and speaking up when something feels off. That moment of pause, that second check, that timely call to pharmacy—that is where Parin’s promise is fulfilled.
As pediatric anticoagulation evolves, one constant remains: the nurse is the final, irreplaceable safeguard. And with Parin, that responsibility is both profound and precise.
For further learning, refer to the 2023 American Society of Hematology (ASH) Clinical Practice Guidelines for Anticoagulation in Children, the PCCM Anticoagulation Toolkit (version 4.1), and the Sandoz Parin Prescribing Information (rev. May 2024). Institutional protocols should be reviewed and updated biannually using data from the HIN Registry and PHIS benchmarking reports.
Remember: Parin doesn’t distinguish between a 500 g micropremie and a 12-year-old with DVT—but your clinical judgment does. Let that judgment be informed, deliberate, and deeply human.
Always prioritize the infant’s developmental stage over chronologic age. A 34-week gestation infant at 4 weeks postnatal age still metabolizes Parin like a younger neonate—not a toddler. This principle guides every decision: from infusion rate to monitoring frequency to family teaching.
Finally, never underestimate the power of consistent documentation. A well-documented aPTT trend tells a story no single value can: rising values may signal accumulation; falling values may precede breakthrough clotting. Charting isn’t clerical work—it’s clinical reasoning made visible.
Parin is more than a drug. It is a responsibility—one measured in microliters, seconds, and lives.
